Patents by Inventor Nancy L. Haigwood
Nancy L. Haigwood has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20080267993Abstract: The invention provides vaccination protocols for administering immunogens to a primate host in order to promote the formation of neutralizing antibodies (NAbs) against primate immunodeficiency viruses. In some embodiments, the vaccination protocols comprise the step of administering to a primate host a first immunogen comprising at least one primate immunodeficiency virus Envelope (env) sequence having a first set of consensus glycosylation sequences, followed by a second immunogen comprising at least one primate immunodeficiency virus env sequence having a second set of consensus glycosylation sequences, wherein the differences between the first set of consensus glycosylation sequences and the second set of consensus glycosylation sequences comprise differences in consensus glycosylation sequences observed in HIV isolates obtained at different time points of a natural infection.Type: ApplicationFiled: March 2, 2007Publication date: October 30, 2008Applicants: Seattle Biomedical Research Institute, University of WashingtonInventors: Nancy L. Haigwood, Wendy Blay, Leonidas Stamatatos
-
Patent number: 5976530Abstract: Novel polypeptide compositions based on the amino acid sequence of tissue plasminogen activator (tPA) are provided having improved properties over natural tissue plasminogen activator. Particularly, enhanced specific activity, reduced response to inhibition by plasminogen activator inhibitor, fibrin stimulation of plasminogenolytic activity and/or enhanced affinity to fibrin surfaces are provided by modifying one or more loci by deletions or substitutions. One or both of the N- or C-termini may be modified.Type: GrantFiled: February 13, 1997Date of Patent: November 2, 1999Assignees: Chiron Corporation, Hoechst Marion Roussel Deutschland GmbHInventors: Nancy L. Haigwood, Guy Mullenbach, Ernst-Guenter Afting, Eric Paul Paques
-
Patent number: 5817792Abstract: HIV-1 envelope muteins are provided comprising deletions within the hypervariable domains of the polypeptides. Methods of using these proteins in immunoassay and to elicit antibody production are also disclosed, as well as materials and methods useful for producing the muteins by recombinant DNA technology.Type: GrantFiled: May 15, 1995Date of Patent: October 6, 1998Assignee: Chiron CorporationInventor: Nancy L. Haigwood
-
Patent number: 5814458Abstract: HIV-1 envelope muteins are provided comprising deletions within the hypervariable domains of the poly-peptides. Methods of using these proteins in immunoassay and to elicit antibody production are also disclosed, as well as materials and methods useful for producing the muteins by recombinant DNA technology.Type: GrantFiled: January 12, 1995Date of Patent: September 29, 1998Assignee: Chiron CorporationInventor: Nancy L. Haigwood
-
Patent number: 5792459Abstract: HIV-1 envelope muteins are provided comprising deletions within the hypervariable domains of the polypeptides. Methods of using these proteins in immunoassay and to elicit antibody production are also disclosed, as well as materials and methods useful for producing the muteins by recombinant DNA technology.Type: GrantFiled: May 15, 1995Date of Patent: August 11, 1998Assignee: Chiron CorporationInventor: Nancy L. Haigwood
-
Patent number: 5696238Abstract: A method for purifying recombinant HIV gp120 so as to provide a glycopeptide having protein/protein binding properties substantially identical to natural viral HIV gp120, which comprises fractionating a composition containing crude gp120 sequentially using (1) ion exchange chromatography, (2) hydrophobic-interaction chromatography, and (3) size exclusion filtration, collecting at each step a fraction that exhibits specific binding affinity for CD4 peptide. The process is carried out in the absence of any affinity purification steps or any steps (such as reverse-phase HPLC) that use contact protein with organic solvents. The product obtained by this method is a purified, full-length, non-fusion recombinant HIV gp120 glycoprotein having protein/protein interaction properties substantially identical to gp120 as presented on an HIV virus, including binding affinity for CD4 and binding affinity for at least one antibody capable of neutralizing HIV infectivity.Type: GrantFiled: May 11, 1995Date of Patent: December 9, 1997Assignee: Chiron CorporationInventors: Nancy L. Haigwood, Carl Scandella
-
Patent number: 5688688Abstract: Polynucleotide sequences are provided for the diagnosis of the presence of retroviral infection in a human host associated with lymphadenopathy syndrome and/or acquired immune deficiency syndrome, for expression of polypeptides and use of the polypeptides to prepare antibodies, where both the polypeptides and antibodies may be employed as diagnostic reagents or in therapy, e.g., vaccines and passive immunization. The sequences provide detection of the viral infectious agents associated with the indicated syndromes and can be used for expression of antigenic polypeptides.Type: GrantFiled: August 10, 1994Date of Patent: November 18, 1997Assignee: Chiron CorporationInventors: Paul A. Luciw, Dino Dina, Steven Rosenberg, Barbara S. Chapman, Richard M. Thayer, Nancy L. Haigwood
-
Patent number: 5656269Abstract: Novel polypeptide compositions based on the amino acid sequence of tissue plasminogen activator (tPA) are provided having improved properties over natural tissue plasminogen activator. Particularly, reduced fibrin stimulation of plasminogenolytic activity and/or enhanced affinity to fibrin surfaces are provided by modifying the C-terminus by deletions.Type: GrantFiled: January 31, 1995Date of Patent: August 12, 1997Assignees: Chiron Corp., Behringwerke AGInventors: Nancy L. Haigwood, Guy Mullenbach, Ernst-Guenter Afting, Eric Paul Paques
-
Patent number: 5653985Abstract: A method for purifying recombinant HIV gp120 so as to provide a glycopeptide having protein/protein binding properties substantially identical to natural viral HIV gp120, which comprises fractionating a composition containing crude gp120 sequentially using (1) ion exchange chromatography, (2) hydrophobic-interaction chromatography, and (3) size exclusion filtration, collecting at each step a fraction that exhibits specific binding affinity for CD4 peptide. The process is carried out in the absence of any affinity purification steps or any steps (such as reverse-phase HPLC) that use contact protein with organic solvents. The product obtained by this method is a purified, full-length, non-fusion recombinant HIV gp120 glycoprotein having protein/protein-interaction properties substantially identical to gp120 as presented on an HIV virus, including binding affinity for CD4 and binding affinity for at least one antibody capable of neutralizing HIV infectivity.Type: GrantFiled: May 11, 1995Date of Patent: August 5, 1997Assignee: Chiron CorporationInventors: Nancy L. Haigwood, Carl Scandella
-
Patent number: 5614612Abstract: A method for purifying recombinant HIV gp120 so as to provide a glycopeptide having protein/protein binding properties substantially identical to natural viral HIV gp120, which comprises fractionating a composition containing crude gp120 sequentially using (1) ion exchange chromatography, (2) hydrophobic-interaction chromatography, and (3) size exclusion filtration, collecting at each step a fraction that exhibits specific binding affinity for CD4 peptide. The process is carried out in the absence of any affinity purification steps or any steps (such as reverse-phase HPLC) that use contact protein with organic solvents. The product obtained by this method is a purified, full-length, non-fusion recombinant HIV gp120 glycoprotein having protein/protein-interaction properties substantially identical to gp120 as presented on an HIV virus, including binding affinity for CD4 and binding affinity for at least one antibody capable of neutralizing HIV infectivity.Type: GrantFiled: May 9, 1994Date of Patent: March 25, 1997Inventors: Nancy L. Haigwood, Carl Scandella
-
Patent number: 5501853Abstract: Novel polypeptide compositions based on the amino acid sequence of tissue plasminogen activator (tPA) are provided having improved properties over natural tissue plasminogen activator. Particularly, enhanced specific activity, reduced response to inhibition by plasminogen activator inhibitor, fibrin stimulation of plasminogenolytic activity and/or enhanced affinity to fibrin surfaces are provided by modifying one or more loci by deletions or substitutions. One or both of the N- or C-termini may be modified.Type: GrantFiled: December 22, 1986Date of Patent: March 26, 1996Assignees: Chiron Corporation, Behringwerke AGInventors: Nancy L. Haigwood, Ernest-Guenter Afting, Guy Mullenbach, Eric P. Paques
-
Patent number: 5439679Abstract: Novel polypeptide compositions based on the amino acid sequence of tissue plasminogen activator (tPA) are provided having improved properties over natural tissue plasminogen activator. Particularly, enhanced specific activity, reduced response to inhibition by plasminogen activator inhibitor, fibrin stimulation of plasminogenolytic activity and/or enhanced affinity to fibrin surfaces are provided by modifying one or more loci by deletions or substitutions. One or both of the N- or C-termini may be modified.The plasmids designated 1, 2 and 3 were deposited at the A.T.C.C. on Dec. 20, 1985 and given A.T.C.C. designations 40214, 40215 and 40216, respectively.Type: GrantFiled: March 10, 1994Date of Patent: August 8, 1995Assignees: Chiron Corporation, Behringwerke AGInventors: Ernest-Guenter Afting, Eric-Paul Paques, Nancy L. Haigwood, Guy Mullenbach
-
Patent number: 5108909Abstract: Improved expression of tPA in mammalian cells is achieved employing a promoter region functional in a mammalian cell with a DNA sequence coding for tPA, where the sequence is interrupted by at least one intron. Particularly, a viral promoter is employed in conjunction with a hybrid gene having portions of the coding sequence uninterrupted by introns as compared to the wild-type gene and coding sequences interrupted by introns or the wild-type gene or mutants thereof.Plasmid pSV7tPA2I was deposited on Feb. 14, 1985 and given A.T.C.C. Accession No. 40163.Type: GrantFiled: September 17, 1987Date of Patent: April 28, 1992Assignee: Chiron CorporationInventor: Nancy L. Haigwood